Table 1.
Clinical and Histopathologic Features with Abnormal or Normal p53 Immunohistochemistry.
| p53 expression by immunohistochemistry |
||||
|---|---|---|---|---|
| All patients (n = 60) | Abnormal (n = 27) | Normal (n = 33) | ||
|
| ||||
| n (%) | n (%) | n (%) | P value | |
|
| ||||
| Age, median (range), years | 64 (range: 47–83) | 66 (range: 50–83) | 62 (range: 47–75) | |
| Sex | ||||
| M | 40 (67%) | 19 (48%) | 21 (52%) | .78 |
| F | 20 (33%) | 8 (40%) | 12 (60%) | |
| Race | ||||
| White | 53 (88%) | 23 (43%) | 30 (57%) | .47 |
| Black or African American | 5 (8%) | 3 (60%) | 2 (40%) | |
| Asian | 1 (2%) | 1 (100%) | 0 (0%) | |
| Hispanic | 1 (2%) | 0 (0%) | 1 (100%) | |
| Underlying malignancy | ||||
| Gastroesophageal adenocarcinoma | 30 (50%) | 17 (57%) | 13 (43%) | .09 |
| Esophageal squamous cell carcinoma | 3 (5%) | 2 (67%) | 1 (33%) | |
| Pancreatic ductal adenocarcinoma | 27 (45%) | 8 (30%) | 19 (70%) | |
| Treatment | ||||
| Chemoradiationa | 54 (90%) | 27 (50%) | 27 (50%) | .06 |
| Chemotherapy only | 6 (10%) | 0 (0%) | 6 (100%) | |
| Interval from last treatment to specimen collection | ||||
| < = 30 days | 12 (20%) | 6 (50%) | 6 (50%) | .62 |
| 3–60 days | 35 (58%) | 17 (49%) | 18 (51%) | |
| >60 days | 12 (20%) | 4 (25%) | 8 (75%) | |
| Unknown | 1 (2%) | 0 (0%) | 1 (100%) | |
| Location | ||||
| Gastroesophageal junction/gastric cardia | 32 (53%) | 18 (56%) | 14 (44%) | .25 |
| Gastric body | 2 (3%) | 1 (50%) | 1 (50%) | |
| Gastric antrum | 24 (40%) | 7 (29%) | 17 (71%) | |
| Pylorus | 2 (3%) | 1 (50%) | 1 (50%) | |
| Therapy-related epithelial changes | ||||
| Present | 50 (83%) | 27 (54%) | 23 (46%) | .005 |
| Absent | 10 (17%) | 0 (0%) | 10 (100%) | |
| Neuroendocrine cell micronests | ||||
| Present | 37 (62%) | 21 (57%) | 16 (43%) | .04 |
| Absent | 23 (38%) | 6 (26%) | 17 (74%) | |
Bold values indicate statistical significance, P value < .05
a
Includes 1 patient treated with chemotherapy and yttrium radioembolization.